Kv1.3 in the spotlight for treating immune diseases

References

• Owen J, Punt J, Stranford S, et al. Kuby Immunology. New York: Macmillan Learning; 2018.
   Google Scholar
• Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. Amsterdam: Elsevier; 2021.
   Google Scholar
• Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. Annu Rev Immunol. 2015;33(1):291–353. doi: 10.1146/annurev-immunol-032414-112212
   PubMed Web of Science ®Google Scholar
• Grissmer S, Ghanshani S, Dethlefs B, et al. The Shaw-related potassium channel gene, Kv3.1, on human chromosome 11, encodes the type l K+ channel in T cells. J Biol Chem. 1992 Oct 15;267(29):20971–20979. doi: 10.1016/S0021-9258(19)36784-5
   PubMed Web of Science ®Google Scholar
• Liu QH, Fleischmann BK, Hondowicz B, et al. Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation. J Exp Med. 2002 Oct 7;196(7):897–909. doi: 10.1084/jem.20020381
   PubMed Web of Science ®Google Scholar
• Vicente R, Escalada A, Villalonga N, et al. Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages. J Biol Chem. 2006 Dec 8;281(49):37675–37685. doi: 10.1074/jbc.M605617200
   PubMed Web of Science ®Google Scholar
• Kuang Q, Purhonen P, Hebert H. Structure of potassium channels. Cell Mol Life Sci. 2015 Oct;72(19):3677–3693. doi: 10.1007/s00018-015-1948-5
   PubMed Web of Science ®Google Scholar
• Beeton C, Wulff H, Standifer NE, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414–17419. doi: 10.1073/pnas.0605136103
   PubMed Web of Science ®Google Scholar
• Gocke AR, Lebson LA, Grishkan IV, et al. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol. 2012 Jun 15;188(12):5877–5886. doi: 10.4049/jimmunol.1103095
   PubMed Web of Science ®Google Scholar
• Khodoun M, Chimote AA, Ilyas FZ, et al. Targeted knockdown of Kv1.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosus. Sci Adv. 2020 Nov;6(47). doi: 10.1126/sciadv.abd1471
   PubMed Web of Science ®Google Scholar
• Kundu-Raychaudhuri S, Chen YJ, Wulff H, et al. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis–xenograft model. J Autoimmun. 2014 Dec;55:63–72.
   PubMed Web of Science ®Google Scholar
• Beeton C, Wulff H, Barbaria J, et al. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13942–13947. doi: 10.1073/pnas.241497298
   PubMed Web of Science ®Google Scholar
• Gulbins E, Sassi N, Grassme H, et al. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochim Biophys Acta. 2010 Jun;1797(6–7):1251–1259.
   PubMed Web of Science ®Google Scholar
• Szabo I, Trentin L, Trimarco V, et al. Biophysical characterization and expression analysis of Kv1.3 potassium channel in primary human leukemic B cells. Cell Physiol Biochem. 2015;37(3):965–978. doi: 10.1159/000430223
   PubMedGoogle Scholar
• Azam P, Sankaranarayanan A, Homerick D, et al. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol. 2007 Jun;127(6):1419–1429.
   PubMed Web of Science ®Google Scholar
• Fan C, Long R, You Y, et al. A novel PADRE-Kv1.3 vaccine effectively induces therapeutic antibodies and ameliorates experimental autoimmune encephalomyelitis in rats. Clin Immunol. 2018 Aug;193:98–109.
   PubMed Web of Science ®Google Scholar
• Fomina AF, Nguyen HM, Wulff H. Kv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling. Channels (Austin). 2021 Dec;15(1):67–78. doi: 10.1080/19336950.2020.1853943
   PubMed Web of Science ®Google Scholar
• Chhabra S, Chang SC, Nguyen HM, et al. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014 Sep;28(9):3952–3964.
   PubMed Web of Science ®Google Scholar
• Han S, Yi H, Yin SJ, et al. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem. 2008 Jul 4;283(27):19058–19065. doi: 10.1074/jbc.M802054200
   PubMed Web of Science ®Google Scholar
• Yang W, Feng J, Wang B, et al. BF9, the first functionally characterized snake toxin peptide with Kunitz-type protease and potassium channel inhibiting properties. J Biochem Mol Toxicol. 2014 Feb;28(2):76–83.
   PubMed Web of Science ®Google Scholar
• Aneiros A, García I, Martínez J, et al. A potassium channel toxin from the secretion of the sea anemone bunodosoma granulifera. isolation, amino acid sequence and biological activity. Biochim Biophys Acta Gen Subj. 1993 May 07;1157(1):86–92. doi: 10.1016/0304-4165(93)90082-J
   PubMed Web of Science ®Google Scholar
• Meng L, Xie Z, Zhang Q, et al. Scorpion potassium channel-blocking defensin highlights a functional link with neurotoxin. J Biol Chem. 2016 Mar 25;291(13):7097–106. doi: 10.1074/jbc.M115.680611
   PubMed Web of Science ®Google Scholar
• Renisio JG, Romi-Lebrun R, Blanc E, et al. Solution structure of BmKTX, a K+ blocker toxin from the Chinese scorpion Buthus Martensi. Proteins. 2000 Jan 1;38(1):70–78. doi: 10.1002/(SICI)1097-0134(20000101)38:1<70:AID-PROT8>3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Zhu L, Gao B, Luo L, et al. Two dyad-free Shaker-type K+ channel blockers from scorpion venom. Toxicon. 2012 Mar 1;59(3):402–407. doi: 10.1016/j.toxicon.2011.11.016
   PubMed Web of Science ®Google Scholar
• Grissmer S, Nguyen AN, Aiyar J, et al. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227–1234.
   PubMed Web of Science ®Google Scholar
• Aiyar J, Withka JM, Rizzi JP, et al. Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins. Neuron. 1995 Nov;15(5):1169–1181.
   PubMed Web of Science ®Google Scholar
• Garcia-Calvo M, Leonard RJ, Novick J, et al. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J Biol Chem. 1993 Sep 5;268(25):18866–18874. doi: 10.1016/S0021-9258(17)46707-X
   PubMed Web of Science ®Google Scholar
• Kharrat R, Mansuelle P, Sampieri F, et al. Maurotoxin, a four disulfide bridge toxin from scorpio maurus venom: purification, structure and action on potassium channels. FEBS Lett. 1997 Apr 14;406(3):284–290. doi: 10.1016/S0014-5793(97)00285-8
   PubMed Web of Science ®Google Scholar
• Mouhat S, Visan V, Ananthakrishnan S, et al. K+ channel types targeted by synthetic OSK1, a toxin from orthochirus scrobiculosus scorpion venom. Biochem J. 2005 Jan 1;385(Pt 1):95–104. doi: 10.1042/BJ20041379
   PubMedGoogle Scholar
• Péter M Jr., Hajdu P, Varga Z, et al. Blockage of human T lymphocyte Kv1.3 channels by Pi1, a novel class of scorpion toxin. Biochem Biophys Res Commun. 2000 Nov 11;278(1):34–37. doi: 10.1006/bbrc.2000.3756
   PubMed Web of Science ®Google Scholar
• Kalman K, Pennington MW, Lanigan MD, et al. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem. 1998 Dec 4;273(49):32697–32707. doi: 10.1074/jbc.273.49.32697
   PubMed Web of Science ®Google Scholar
• Chi V, Pennington MW, Norton RS, et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon. 2012 Mar 15;59(4):529–546. doi: 10.1016/j.toxicon.2011.07.016
   PubMed Web of Science ®Google Scholar
• Varga Z, Gurrola-Briones G, Papp F, et al. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012 Sep;82(3):372–382.
   PubMed Web of Science ®Google Scholar
• Bodendiek SB, Mahieux C, Hansel W, et al. 4-phenoxybutoxy-substituted heterocycles–a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem. 2009 May;44(5):1838–1852.
   PubMed Web of Science ®Google Scholar
• Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254–1270.
   PubMed Web of Science ®Google Scholar
• Vennekamp J, Wulff H, Beeton C, et al. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364–1374.
   PubMed Web of Science ®Google Scholar
• Ren YR, Pan F, Parvez S, et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One. 2008;3(12):e4009. doi: 10.1371/journal.pone.0004009
   PubMed Web of Science ®Google Scholar
• Unterweger AL, Jensen MO, Giordanetto F, et al. Suppressing Kv1.3 ion channel activity with a novel small molecule inhibitor ameliorates inflammation in a humanised mouse model of ulcerative colitis. J Crohn's Colitis. 2021 Nov 8;15(11):1943–1958. doi: 10.1093/ecco-jcc/jjab078
   Google Scholar
• Nguyen W, Howard BL, Jenkins DP, et al. Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7106–7109. doi: 10.1016/j.bmcl.2012.09.080
   PubMed Web of Science ®Google Scholar
• Xie Z, Zhao Y, Yang W, et al. Methotrexate, a small molecular scaffold targeting Kv1.3 channel extracellular pore region. Biochem Biophys Res Commun. 2020 Nov 5;532(2):265–270. doi: 10.1016/j.bbrc.2020.08.050
   PubMed Web of Science ®Google Scholar
• Bednenko J, Harriman R, Marien L, et al. A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3 [research support, non-U.S. Gov’t] mAbs. 2018 May;10(4):636–650.
   PubMed Web of Science ®Google Scholar
• Hajdu P, Chimote AA, Thompson TH, et al. Functionalized liposomes loaded with siRnas targeting ion channels in effector memory T cells as a potential therapy for autoimmunity. Biomaterials. 2013 Dec;34(38):10249–10257.
   PubMed Web of Science ®Google Scholar
• Fischer HG, Eder C. Voltage-gated K+ currents of mouse dendritic cells. FEBS Lett. 1995 Oct 9;373(2):127–130. doi: 10.1016/0014-5793(95)01029-E
   PubMed Web of Science ®Google Scholar
• Mullen KM, Rozycka M, Rus H, et al. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann Neurol. 2006 Jul;60(1):118–127.
   PubMed Web of Science ®Google Scholar
• Shumilina E, Zahir N, Xuan NT, et al. Phosphoinositide 3-kinase dependent regulation of kv channels in dendritic cells. Cell Physiol Biochem. 2007;20(6):801–8. doi: 10.1159/000110440
   PubMedGoogle Scholar
• Vallejo-Gracia A, Sastre D, Colomer-Molera M, et al. KCNE4-dependent functional consequences of Kv1.3-related leukocyte physiology. Sci Rep. 2021 Jul 16;11(1):14632. doi: 10.1038/s41598-021-94015-9
   PubMed Web of Science ®Google Scholar
• Dong X, Wei L, Guo X, et al. Dlg1 maintains dendritic cell function by securing voltage-gated K(+) channel integrity. J Immunol. 2019 Jun 1;202(11):3187–3197. doi: 10.4049/jimmunol.1900089
   PubMed Web of Science ®Google Scholar
• Zsiros E, Kis-Toth K, Hajdu P, et al. Developmental switch of the expression of ion channels in human dendritic cells. J Immunol. 2009 Oct 1;183(7):4483–92. doi: 10.4049/jimmunol.0803003
   PubMed Web of Science ®Google Scholar
• Hsu S, O’Connell PJ, Klyachko VA, et al. Fundamental Ca2+ signaling mechanisms in mouse dendritic cells: CRAC is the major Ca2+ entry pathway. J Immunol. 2001 May 15;166(10):6126–33. doi: 10.4049/jimmunol.166.10.6126
   PubMed Web of Science ®Google Scholar
• Qi H, Denning TL, Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun. 2003 Jun;71(6):3337–42. doi: 10.1128/IAI.71.6.3337-3342.2003
   PubMed Web of Science ®Google Scholar
• Xuan NT, Shumilina E, Matzner N, et al. Ca2±dependent functions in peptidoglycan-stimulated mouse dendritic cells. Cell Physiol Biochem. 2009;24(3–4):167–176. doi: 10.1159/000233243
   PubMedGoogle Scholar
• Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014 Mar 4;19(3):373–9. doi: 10.1016/j.cmet.2014.01.001
   PubMed Web of Science ®Google Scholar
• Tyan L, Sopjani M, Dermaku-Sopjani M, et al. Inhibition of voltage-gated K+ channels in dendritic cells by rapamycin. Am J Physiol Cell Physiol. 2010 Dec;299(6):C1379–85.
   PubMed Web of Science ®Google Scholar
• Vicente R, Escalada A, Coma M, et al. Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J Biol Chem. 2003 Nov 21;278(47):46307–20. doi: 10.1074/jbc.M304388200
   PubMed Web of Science ®Google Scholar
• Villalonga N, David M, Bielanska J, et al. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels. Biochem Pharmacol. 2010 Sep 15;80(6):858–66. doi: 10.1016/j.bcp.2010.05.012
   PubMed Web of Science ®Google Scholar
• Leanza L, Zoratti M, Gulbins E, et al. Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Curr Med Chem. 2012;19(31):5394–404. doi: 10.2174/092986712803833281
   PubMed Web of Science ®Google Scholar
• Mackenzie AB, Chirakkal H, North RA. Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2003 Oct;285(4):L862–8. doi: 10.1152/ajplung.00095.2003
   PubMed Web of Science ®Google Scholar
• Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32(6):463–488. doi: 10.1615/CritRevImmunol.v32.i6.10
   PubMed Web of Science ®Google Scholar
• Chen YJ, Nguyen HM, Maezawa I, et al. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Ann Clin Transl Neurol. 2018 Feb;5(2):147–161.
   PubMed Web of Science ®Google Scholar
• Wu BM, Liu JD, Li YH, et al. Margatoxin mitigates CCl4‑induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and STAT signaling. Int J Mol Med. 2020 Jan;45(1):103–114.
   PubMed Web of Science ®Google Scholar
• Huff MW, Daugherty A, Lu H. Chapter 18 - atherosclerosis. In: Ridgway N McLeod R, editors Biochemistry of lipids, lipoproteins and membranes. Sixth ed. Boston: Elsevier; 2016. p. 519–548.
   Google Scholar
• Lei XJ, Ma AQ, Xi YT, et al. Inhibitory effects of blocking voltage-dependent potassium channel 1.3 on human monocyte-derived macrophage differentiation into foam cells. Beijing Da Xue Xue Bao Yi Xue Ban Journal of Peking University (Health Sciences) . 2006 Jun 18;38(3):257–261.
   Google Scholar
• Yang Y, Wang YF, Yang XF, et al. Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL. J Lipid Res. 2013 Jan;54(1):34–43.
   PubMed Web of Science ®Google Scholar
• Kan XH, Gao HQ, Ma ZY, et al. Kv1.3 potassium channel mediates macrophage migration in atherosclerosis by regulating ERK activity. Arch Biochem Biophys. 2016 Feb 1;591:150–6. doi: 10.1016/j.abb.2015.12.013
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu L, Hu Y, et al. Kv1.3 channel is involved in ox-LDL-induced macrophage inflammation via ERK/NF-κB signaling pathway. Arch Biochem Biophys. 2022 Nov 15;730:109394.
   PubMed Web of Science ®Google Scholar
• Gao T, Raza SA, Ramesha S, et al. Temporal profiling of Kv1.3 channel expression in brain mononuclear phagocytes following ischemic stroke. J Neuroinflammation. 2019 Jun 1;16(1):116. doi: 10.1186/s12974-019-1510-8
   PubMedGoogle Scholar
• Wu B, Liu JD, Bian E, et al. Blockage of Kv1.3 regulates macrophage migration in acute liver injury by targeting δ-catenin through RhoA signaling. Int J Biol Sci. 2020;16(4):671–681. doi: 10.7150/ijbs.38950
   PubMed Web of Science ®Google Scholar
• Khemili D, Valenzuela C, Laraba-Djebari F, et al. Differential effect of androctonus australis hector venom components on macrophage K(V) channels: electrophysiological characterization. Eur Biophys J. 2019 Jan;48(1):1–13.
   PubMed Web of Science ®Google Scholar
• Deng Z, Zeng Q, Tang J, et al. Anti-inflammatory effects of FS48, the first potassium channel inhibitor from the salivary glands of the flea xenopsylla cheopis. J Biol Chem. 2021 Jan;296:100670.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sang M, Zhang Y, et al. BmKK2, a thermostable Kv1.3 blocker from buthus martensii Karsch (BmK) scorpion, inhibits the activation of macrophages via Kv1.3-NF-kappaB- NLRP3 axis. J Ethnopharmacol. 2023 Oct 5;314:116624. doi: 10.1016/j.jep.2023.116624
   PubMed Web of Science ®Google Scholar
• Gomez-Budia M, Konttinen H, Saveleva L, et al. Glial smog: interplay between air pollution and astrocyte-microglia interactions. Neurochem Int. 2020 Jun;136:104715.
   PubMed Web of Science ®Google Scholar
• Cayabyab FS, Khanna R, Jones OT, et al. Suppression of the rat microglia Kv1.3 current by src-family tyrosine kinases and oxygen/glucose deprivation. Eur J Neurosci. 2000 Jun;12(6):1949–60.
   PubMed Web of Science ®Google Scholar
• Pannasch U, Farber K, Nolte C, et al. The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia. Mol Cell Neurosci. 2006 Dec;33(4):401–11.
   PubMed Web of Science ®Google Scholar
• Kotecha SA, Schlichter LC. A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci. 1999 Dec 15;19(24):10680–93. doi: 10.1523/JNEUROSCI.19-24-10680.1999
   PubMed Web of Science ®Google Scholar
• Anton R, Ghenghea M, Ristoiu V, et al. Potassium channels Kv1.3 and Kir2.1 but not Kv1.5 contribute to BV2 cell line and primary microglial migration. Int J Mol Sci. 2021 Feb 19;22(4):2081. doi: 10.3390/ijms22042081
   PubMed Web of Science ®Google Scholar
• Grimaldi A, D’Alessandro G, Di Castro MA, et al. Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma. Sci Rep. 2018 May 16;8(1):7654. doi: 10.1038/s41598-018-25940-5
   PubMedGoogle Scholar
• Nguyen HM, di Lucente J, Chen YJ, et al. Biophysical basis for Kv1.3 regulation of membrane potential changes induced by P2X4-mediated calcium entry in microglia. Glia. 2020 Nov;68(11):2377–2394.
   PubMed Web of Science ®Google Scholar
• Rangaraju S, Raza SA, Pennati A, et al. A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. J Neuroinflammation. 2017 Jun 26;14(1):128. doi: 10.1186/s12974-017-0906-6
   PubMedGoogle Scholar
• Fordyce CB, Jagasia R, Zhu X, et al. Microglia Kv1.3 channels contribute to their ability to kill neurons. J Neurosci. 2005 Aug 3;25(31):7139–49. doi: 10.1523/JNEUROSCI.1251-05.2005
   PubMed Web of Science ®Google Scholar
• Schilling T, Eder C. Effects of kinase inhibitors on TGF-beta induced upregulation of Kv1.3 K+ channels in brain macrophages. Pflugers Arch. 2003 Dec;447(3):312–315. doi: 10.1007/s00424-003-1155-3
   PubMed Web of Science ®Google Scholar
• Schilling T, Quandt FN, Cherny VV, et al. Upregulation of Kv1.3 K(+) channels in microglia deactivated by TGF-beta. Am J Physiol Cell Physiol. 2000 Oct;279(4):C1123–34.
   PubMed Web of Science ®Google Scholar
• Lively S, Lam D, Wong R, et al. Comparing effects of transforming growth factor β1 on microglia from rat and mouse: transcriptional profiles and potassium channels. Front Cell Neurosci. 2018;12:115. doi: 10.3389/fncel.2018.00115
   PubMed Web of Science ®Google Scholar
• Siddiqui TA, Lively S, Schlichter LC. Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia. J Neuroinflammation. 2016 Mar 24;13(1):66. doi: 10.1186/s12974-016-0531-9
   PubMedGoogle Scholar
• Nguyen HM, Grossinger EM, Horiuchi M, et al. Differential Kv1.3, KCa3.1, and Kir2.1 expression in “classically” and “alternatively” activated microglia. Glia. 2017 Jan;65(1):106–121.
   PubMed Web of Science ®Google Scholar
• Charolidi N, Schilling T, Eder C, et al. Microglial Kv1.3 channels and P2Y12 receptors differentially regulate cytokine and chemokine release from brain slices of young adult and aged mice. PLoS One. 2015;10(5):e0128463. doi: 10.1371/journal.pone.0128463
   PubMed Web of Science ®Google Scholar
• Di Lucente J, Nguyen HM, Wulff H, et al. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia. 2018 Sep;66(9):1881–1895.
   PubMed Web of Science ®Google Scholar
• Ma DC, Zhang NN, Zhang YN, et al. Kv1.3 channel blockade alleviates cerebral ischemia/reperfusion injury by reshaping M1/M2 phenotypes and compromising the activation of NLRP3 inflammasome in microglia. Exp Neurol. 2020 Oct;332:113399.
   PubMed Web of Science ®Google Scholar
• Yuan X, Han S, Manyande A, et al. Spinal voltage-gated potassium channel Kv1.3 contributes to neuropathic pain via the promotion of microglial M1 polarization and activation of the NLRP3 inflammasome. Eur J Pain. 2023 Feb;27(2):289–302.
   PubMed Web of Science ®Google Scholar
• Gao S, Zou X, Wang Z, et al. Bergapten attenuates microglia-mediated neuroinflammation and ischemic brain injury by targeting Kv1.3 and carbonyl reductase 1. Eur J Pharmacol. 2022 Oct 15;933:175242. doi: 10.1016/j.ejphar.2022.175242
   PubMed Web of Science ®Google Scholar
• Menteyne A, Levavasseur F, Audinat E, et al. Predominant functional expression of Kv1.3 by activated microglia of the hippocampus after status epilepticus. PLoS One. 2009 Aug 26;4(8):e6770. doi: 10.1371/journal.pone.0006770
   PubMed Web of Science ®Google Scholar
• Khanna R, Roy L, Zhu X, et al. K+ channels and the microglial respiratory burst. Am J Physiol Cell Physiol. 2001 Apr;280(4):C796–806.
   PubMed Web of Science ®Google Scholar
• Nicolazzo JA, Pan Y, Di Stefano I, et al. Blockade of microglial Kv1.3 potassium channels by the peptide HsTX1[R14A] attenuates lipopolysaccharide-mediated neuroinflammation. J Pharm Sci. 2022 Mar;111(3):638–647.
   PubMed Web of Science ®Google Scholar
• Rangaraju S, Gearing M, Jin LW, et al. Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer’s disease. J Alzheimers Dis. 2015;44(3):797–808. doi: 10.3233/JAD-141704
   PubMed Web of Science ®Google Scholar
• Chen YJ, Cui Y, Singh L, et al. The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion. Ann Clin Transl Neurol. 2021 Oct;8(10):2070–2082.
   PubMed Web of Science ®Google Scholar
• Lee RD, Chen YJ, Singh L, et al. Immunocytoprotection after reperfusion with Kv1.3 inhibitors has an extended treatment window for ischemic stroke. Front Pharmacol. 2023;14:1190476. doi: 10.3389/fphar.2023.1190476
   PubMed Web of Science ®Google Scholar
• Chung S, Lee J, Joe EH, et al. Beta-amyloid peptide induces the expression of voltage dependent outward rectifying K+ channels in rat microglia. Neurosci Lett. 2001 Mar 9;300(2):67–70. doi: 10.1016/S0304-3940(01)01516-6
   PubMed Web of Science ®Google Scholar
• Maezawa I, Nguyen HM, Di Lucente J, et al. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer’s disease: preclinical proof of concept. Brain. 2018 Feb 1;141(2):596–612. doi: 10.1093/brain/awx346
   PubMedGoogle Scholar
• Schilling T, Eder C. Amyloid-beta-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia. J Cell Physiol. 2011 Dec;226(12):3295–3302. doi: 10.1002/jcp.22675
   PubMed Web of Science ®Google Scholar
• Ramesha S, Rayaprolu S, Bowen CA, et al. Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2021 Mar 16;118(11). doi: 10.1073/pnas.2013545118
   PubMed Web of Science ®Google Scholar
• Rangaraju S, Dammer EB, Raza SA, et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease. Mol Neurodegener. 2018 May 21;13(1):24. doi: 10.1186/s13024-018-0254-8
   PubMedGoogle Scholar
• Pan Y, Kagawa Y, Sun J, et al. Peripheral administration of the Kv1.3-blocking peptide HsTX1[R14A] improves cognitive performance in senescence accelerated SAMP8 mice. Neurotherapeutics. 2023 May 24;20(4):1198–1214. doi: 10.1007/s13311-023-01387-z
   PubMed Web of Science ®Google Scholar
• Sarkar S, Nguyen HM, Malovic E, et al. Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson’s disease. J Clin Invest. 2020 Aug 3;130(8):4195–4212. doi: 10.1172/JCI136174
   PubMed Web of Science ®Google Scholar
• Liu J, Xu C, Chen L, et al. Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity. Cell Death Dis. 2012 Jan 19;3(1):e254. doi: 10.1038/cddis.2011.140
   PubMedGoogle Scholar
• Liu J, Xu P, Collins C, et al. HIV-1 Tat protein increases microglial outward K(+) current and resultant neurotoxic activity. PLoS One. 2013;8(5):e64904. doi: 10.1371/journal.pone.0064904
   PubMed Web of Science ®Google Scholar
• Elson A, Anuj A, Barnea-Zohar M, et al. The origins and formation of bone-resorbing osteoclasts. Bone. 2022 Nov;164:116538.
   PubMed Web of Science ®Google Scholar
• Komarova SV, Dixon SJ, Sims SM. Osteoclast ion channels: potential targets for antiresorptive drugs. Curr Pharm Des. 2001 May;7(8):637–654. doi: 10.2174/1381612013397799
   PubMed Web of Science ®Google Scholar
• Arkett SA, Dixon J, Yang JN, et al. Mammalian osteoclasts express a transient potassium channel with properties of Kv1.3. Recept Channels. 1994;2(4):281–293.
   PubMedGoogle Scholar
• Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013 Mar;13(3):159–75. doi: 10.1038/nri3399
   PubMed Web of Science ®Google Scholar
• Immler R, Nadolni W, Bertsch A, et al. The voltage-gated potassium channel KV1.3 regulates neutrophil recruitment during inflammation. Cardiovasc Res. 2022 Mar 25;118(5):1289–1302. doi: 10.1093/cvr/cvab133
   PubMed Web of Science ®Google Scholar
• Burn GL, Foti A, Marsman G, et al. The Neutrophil. Immunity. 2021 Jul 13;54(7):1377–1391. doi: 10.1016/j.immuni.2021.06.006
   PubMed Web of Science ®Google Scholar
• Immler R, Simon SI, Sperandio M. Calcium signalling and related ion channels in neutrophil recruitment and function. Eur J Clin Invest. 2018 Nov;48(Suppl 2):e12964. doi: 10.1111/eci.12964
   PubMedGoogle Scholar
• Xu D, Lu W. Defensins: a double-edged sword in Host immunity. Front Immunol. 2020;11:764. doi: 10.3389/fimmu.2020.00764
   PubMed Web of Science ®Google Scholar
• Xie Z, Feng J, Yang W, et al. Human alpha-defensins are immune-related Kv1.3 channel inhibitors: new support for their roles in adaptive immunity. FASEB J. 2015 Oct;29(10):4324–4333.
   PubMed Web of Science ®Google Scholar
• Grimes D, Johnson R, Pashos M, et al. ORAI1 and ORAI2 modulate murine neutrophil calcium signaling, cellular activation, and host defense. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24403–24414. doi: 10.1073/pnas.2008032117
   PubMed Web of Science ®Google Scholar
• Schlichter L, Sidell N, Hagiwara S. Potassium channels mediate killing by human natural killer cells. Proc Natl Acad Sci, USA. 1986 Jan 01;83(2):451–455.
   PubMed Web of Science ®Google Scholar
• Sidell N, Schlichter LC, Wright SC, et al. Potassium channels in human NK cells are involved in discrete stages of the killing process. J Immunol. 1986 Sep 1;137(5):1650–8. doi: 10.4049/jimmunol.137.5.1650
   PubMed Web of Science ®Google Scholar
• Koshy S, Wu D, Hu X, et al. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013;8(10):e76740. doi: 10.1371/journal.pone.0076740
   PubMed Web of Science ®Google Scholar
• Schulte-Mecklenbeck A, Bittner S, Ehling P, et al. The two-pore domain K2 P channel TASK2 drives human NK-cell proliferation and cytolytic function. Eur J Immunol. 2015 Sep;45(9):2602–14.
   PubMed Web of Science ®Google Scholar
• Geng J, Wang Y, Zhang L, et al. The cajanine derivative LJ101019C regulates the proliferation and enhances the activity of NK cells via Kv1.3 channel-driven activation of the AKT/mTOR pathway. Phytomedicine. 2020 Jan;66:153113.
   PubMed Web of Science ®Google Scholar
• Chandy KG, Williams CB, Spencer RH, et al. A family of three mouse potassium channel genes with intronless coding regions. Science. 1990 Feb 23;247(4945):973–5. doi: 10.1126/science.2305265
   PubMed Web of Science ®Google Scholar
• Panyi G, Vamosi G, Bacso Z, et al. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1285–90. doi: 10.1073/pnas.0307421100
   PubMed Web of Science ®Google Scholar
• Wulff H, Calabresi PA, Allie R, et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003 Jun;111(11):1703–1713.
   PubMed Web of Science ®Google Scholar
• Pang B, Zheng H, Shin DH, et al. TNF-alpha inhibits the CD3-mediated upregulation of voltage-gated K+ channel (Kv1.3) in human T cells. Biochem Biophys Res Commun. 2010 Jan 1;391(1):909–914. doi: 10.1016/j.bbrc.2009.11.162
   PubMed Web of Science ®Google Scholar
• Kang JA, Park SH, Jeong SP, et al. Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8771–6. doi: 10.1073/pnas.1502166113
   PubMed Web of Science ®Google Scholar
• Navarro-Perez M, Estadella I, Benavente-Garcia A, et al. The phosphorylation of Kv1.3: a modulatory mechanism for a multifunctional ion channel. Cancers (Basel). 2023 May 11;15(10):2716. doi: 10.3390/cancers15102716
   PubMed Web of Science ®Google Scholar
• Roig SR, Cassinelli S, Navarro-Perez M, et al. S-acylation-dependent membrane microdomain localization of the regulatory Kvbeta2.1 subunit. Cell Mol Life Sci. 2022 Apr 9;79(5):230. doi: 10.1007/s00018-022-04269-3
   PubMed Web of Science ®Google Scholar
• Capera J, Perez-Verdaguer M, Navarro-Perez M, et al. Kv1.3 controls mitochondrial dynamics during cell cycle progression. Cancers (Basel). 2021 Sep 4;13(17):4457. doi: 10.3390/cancers13174457
   PubMed Web of Science ®Google Scholar
• Capera J, Perez-Verdaguer M, Peruzzo R, et al. A novel mitochondrial Kv1.3-caveolin axis controls cell survival and apoptosis. Elife. 2021 Jul 1;10. doi: 10.7554/eLife.69099
   PubMed Web of Science ®Google Scholar
• Markakis I, Charitakis I, Beeton C, et al. Kv1.3 channel up-regulation in peripheral blood T lymphocytes of patients with multiple sclerosis. Front Pharmacol. 2021;12:714841. doi: 10.3389/fphar.2021.714841
   PubMed Web of Science ®Google Scholar
• Conforti L, Petrovic M, Mohammad D, et al. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation. J Immunol. 2003 Jan 15;170(2):695–702. doi: 10.4049/jimmunol.170.2.695
   PubMed Web of Science ®Google Scholar
• Koni PA, Khanna R, Chang MC, et al. Compensatory anion currents in Kv1.3 channel-deficient thymocytes. J Biol Chem. 2003 Oct 10;278(41):39443–51. doi: 10.1074/jbc.M304879200
   PubMed Web of Science ®Google Scholar
• Hajdu P, Martin GV, Chimote AA, et al. The C-terminus SH3-binding domain of Kv1.3 is required for the actin-mediated immobilization of the channel via cortactin. Mol Biol Cell. 2015 May 1;26(9):1640–51. doi: 10.1091/mbc.E14-07-1195
   PubMed Web of Science ®Google Scholar
• Szilagyi O, Boratko A, Panyi G, et al. The role of PSD-95 in the rearrangement of Kv1.3 channels to the immunological synapse. Pflugers Arch - Eur J Physiol. 2013 Sep;465(9):1341–53.
   PubMed Web of Science ®Google Scholar
• Panyi G, Varga Z, Gaspar R. Ion channels and lymphocyte activation. Immunol Lett. 2004 Mar 29;92(1–2):55–66. doi: 10.1016/j.imlet.2003.11.020
   PubMed Web of Science ®Google Scholar
• Levite M, Cahalon L, Peretz A, et al. Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and β1 integrins. J Exp Med. 2000 Apr 3;191(7):1167–1176. doi: 10.1084/jem.191.7.1167
   PubMed Web of Science ®Google Scholar
• Nicolaou SA, Neumeier L, Steckly A, et al. Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes. J Immunol. 2009 Nov 15;183(10):6296–302. doi: 10.4049/jimmunol.0900613
   PubMed Web of Science ®Google Scholar
• Nicolaou SA, Szigligeti P, Neumeier L, et al. Altered dynamics of Kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus. J Immunol. 2007 Jul 1;179(1):346–56. doi: 10.4049/jimmunol.179.1.346
   PubMed Web of Science ®Google Scholar
• Toth A, Szilagyi O, Krasznai Z, et al. Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse. Immunol Lett. 2009 Jun 30;125(1):15–21. doi: 10.1016/j.imlet.2009.05.004
   PubMed Web of Science ®Google Scholar
• Capera J, Jainarayanan A, Navarro-Perez M, et al. Dynamics and spatial organization of Kv1.3 at the immunological synapse of human CD4+ T cells. Biophys J. 2023 Aug 18; doi: 10.1016/j.bpj.2023.08.011
   Google Scholar
• Szabo I, Bock J, Jekle A, et al. A novel potassium channel in lymphocyte mitochondria. J Biol Chem. 2005 Apr 1;280(13):12790–8. doi: 10.1074/jbc.M413548200
   PubMed Web of Science ®Google Scholar
• Leanza L, Venturini E, Kadow S, et al. Targeting a mitochondrial potassium channel to fight cancer. Cell Calcium. 2015 Jul;58(1):131–8.
   PubMed Web of Science ®Google Scholar
• Leanza L, Romio M, Becker KA, et al. Direct pharmacological targeting of a mitochondrial ion channel selectively kills tumor cells in vivo. Cancer Cell. 2017 Apr 10;31(4):516–531 e10. doi: 10.1016/j.ccell.2017.03.003
   PubMed Web of Science ®Google Scholar
• Felzen B, Lavy R, Garcia M, et al. Interaction of cytotoxic T lymphocytes and guinea pig ventricular myocytes. Pharmacological modulation by blocking K+ currents in cytotoxic T lymphocytes. Circ Res. 1996 Feb;78(2):253–61.
   PubMed Web of Science ®Google Scholar
• Sharma B. Inhibition of the generation of cytotoxic lymphocytes by potassium ion channel blockers. Immunology. 1988 Sep;65(1):101–5.
   PubMed Web of Science ®Google Scholar
• Cahalan MD, Wulff H, Chandy KG. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol. 2001 Jul;21(4):235–52. doi: 10.1023/A:1010958907271
   PubMed Web of Science ®Google Scholar
• Fung-Leung WP, Edwards W, Liu Y, et al. T cell subset and stimulation strength-dependent modulation of T cell activation by Kv1.3 blockers. PLoS One. 2017;12(1):e0170102. doi: 10.1371/journal.pone.0170102
   PubMed Web of Science ®Google Scholar
• Benoist C, Mathis D. Treg cells, life history, and diversity. Cold Spring Harb Perspect Biol. 2012 Sep 1;4(9):a007021. doi: 10.1101/cshperspect.a007021
   PubMed Web of Science ®Google Scholar
• Orban C, Bajnok A, Vasarhelyi B, et al. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets. Cytometry Pt A. 2014 Jul;85(7):636–41.
   PubMedGoogle Scholar
• Vinnenberg L, Bock S, Hundehege P, et al. ImpacT of diverse ion channels on regulatory T cell functions. Cell Physiol Biochem. 2021 May 28;55(S3):145–156.
   PubMedGoogle Scholar
• Varga Z, Csepany T, Papp F, et al. Potassium channel expression in human CD4+ regulatory and naive T cells from healthy subjects and multiple sclerosis patients. Immunol Lett. 2009 Jun 4;124(2):95–101. doi: 10.1016/j.imlet.2009.04.008
   PubMed Web of Science ®Google Scholar
• Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004 Apr 5;199(7):971–9. doi: 10.1084/jem.20031579
   PubMed Web of Science ®Google Scholar
• Wei L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Exp Mol Pathol. 2011 Feb;90(1):74–8. doi: 10.1016/j.yexmp.2010.10.004
   PubMed Web of Science ®Google Scholar
• Shao PP, Liu CJ, Xu Q, et al. Eplerenone reverses cardiac fibrosis via the suppression of tregs by inhibition of Kv1.3 channel. Front Physiol. 2018;9:899. doi: 10.3389/fphys.2018.00899
   PubMed Web of Science ®Google Scholar
• Salam AM. Selective aldosterone blockade with eplerenone in patients with congestive heart failure. Expert Opin Investig Drugs. 2003 Aug;12(8):1423–7. doi: 10.1517/13543784.12.8.1423
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang X, Ju C, et al. Blockage of K(Ca)3.1 and Kv1.3 channels of the B lymphocyte decreases the inflammatory monocyte chemotaxis [research support, non-U.S. Gov’t]. Int Immunopharmacol. 2016 Feb;31:266–271.
   PubMed Web of Science ®Google Scholar
• Wulff H, Knaus HG, Pennington M, et al. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol. 2004 Jul 15;173(2):776–86. doi: 10.4049/jimmunol.173.2.776
   PubMed Web of Science ®Google Scholar
• Vallejo-Gracia A, Bielanska J, Hernandez-Losa J, et al. Emerging role for the voltage-dependent K+ channel Kv1.5 in B-lymphocyte physiology: expression associated with human lymphoma malignancy. J Leukocyte Biol. 2013 Oct;94(4):779–89.
   PubMed Web of Science ®Google Scholar
• Wang LH, Wang N, Lu XY, et al. Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcgammaRIIB receptors. Biochim Biophys Acta. 2012 Feb;1823(2):505–513.
   PubMed Web of Science ®Google Scholar
• Land J, Lintermans LL, Stegeman CA, et al. Kv1.3 channel blockade modulates the effector function of B cells in granulomatosis with polyangiitis. Front Immunol. 2017;8:1205. doi: 10.3389/fimmu.2017.01205
   PubMed Web of Science ®Google Scholar
• Moritoki Y, Lian ZX, Wulff H, et al. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology. 2007 Feb;45(2):314–22.
   PubMed Web of Science ®Google Scholar
• de la Cruz A, Vera-Zambrano A, Peraza DA, et al. Fludarabine inhibits K(V)1.3 currents in human B lymphocytes. Front Pharmacol. 2017;8:177. doi: 10.3389/fphar.2017.00177
   PubMed Web of Science ®Google Scholar
• Severin F, Urbani A, Varanita T, et al. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model. J Exp Clin Cancer Res. 2022 Feb 16;41(1):64. doi: 10.1186/s13046-022-02249-w
   PubMed Web of Science ®Google Scholar
• Pennington MW, Beeton C, Galea CA, et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol. 2009 Apr;75(4):762–73. doi: 10.1124/mol.108.052704.
   PubMed Web of Science ®Google Scholar
• Toldi G, Munoz L, Herrmann M, et al. The effects of Kv1.3 and IKCa1 channel inhibition on cytokine production and calcium influx of T lymphocytes in rheumatoid arthritis and ankylosing spondylitis. Immunol Res. 2016 Apr;64(2):627–31. doi: 10.1007/s12026-015-8683-8.
   PubMed Web of Science ®Google Scholar
• Tarcha EJ, Olsen CM, Probst P, et al. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial. PLoS One. 2017;12(7):e0180762. doi: 10.1371/journal.pone.0180762.
   PubMed Web of Science ®Google Scholar
• Lioudyno V, Abdurasulova I, Negoreeva I, et al. A common genetic variant rs2821557 in KCNA3 is linked to the severity of multiple sclerosis. J Neurosci Res. 2021 Jan;99(1):200–208.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qiu W, Liu J, et al. Blockade of Kv1.3 potassium channel inhibits CD8(+) T cell-mediated neuroinflammation via PD-1/Blimp-1 signaling. FASEB J. 2020 Nov;34(11):15492–15503.
   PubMed Web of Science ®Google Scholar
• Beeton C, Pennington MW, Wulff H, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr;67(4):1369–81.
   PubMed Web of Science ®Google Scholar
• Nicolaou SA, Neumeier L, Takimoto K, et al. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus. Cell Calcium. 2010 Jan;47(1):19–28.
   PubMed Web of Science ®Google Scholar
• Poulopoulou C, Papadopoulou-Daifoti Z, Hatzimanolis A, et al. Glutamate levels and activity of the T cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus. Arthritis Rheum. 2008 May;58(5):1445–50.
   PubMedGoogle Scholar
• Stevens A, Yuasa M, Peckham D, et al. THU0285 Dalazatide, an inhibitor of the Kv1.3 channel on activated effector memory T cells, has immunotherapy potential in systemic lupus erythematosus. Ann Rheumatic Dis. 2016;3(Suppl 1):A3–A4. doi: 10.1136/annrheumdis-2016-eular.5866
   Google Scholar
• Bajnok A, Kaposi A, Kovacs L, et al. Analysis by flow cytometry of calcium influx kinetics in peripheral lymphocytes of patients with rheumatoid arthritis. Cytometry A. 2013 Mar;83(3):287–293.
   PubMedGoogle Scholar
• Lian YT, Yang XF, Wang ZH, et al. Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities. Phytother Res. 2013 Sep;27(9):1321–7.
   PubMed Web of Science ®Google Scholar
• Zou Y, Zhao Q, Zhang X, et al. The immunosuppressive effects and mechanisms of loureirin B on collagen-induced arthritis in rats. Front Immunol. 2023;14:1094649. doi: 10.3389/fimmu.2023.1094649
   PubMed Web of Science ®Google Scholar
• Tanner MR, Tajhya RB, Huq R, et al. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clin Immunol. 2017 Jul;180:45–57.
   PubMed Web of Science ®Google Scholar
• Toldi G, Bajnok A, Dobi D, et al. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis. Immunobiology. 2013 Mar;218(3):311–6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu D, Ortiz-Velez LC, et al. A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis. Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2211977120. doi: 10.1073/pnas.2211977120
   PubMed Web of Science ®Google Scholar
• Kang D, Li B, Luo L, et al. Curcumin shows excellent therapeutic effect on psoriasis in mouse model. Biochimie. 2016 Apr;123:73–80.
   PubMed Web of Science ®Google Scholar
• Ueyama A, Imura K, Kasai-Yamamoto E, et al. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model. Clin Exp Dermatol. 2013 Dec;38(8):897–903.
   PubMed Web of Science ®Google Scholar
• Toldi G, Vasarhelyi B, Kaposi A, et al. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels. Immunol Lett. 2010 Sep 6;133(1):35–41. doi: 10.1016/j.imlet.2010.06.009
   PubMed Web of Science ®Google Scholar
• Orban C, Szabo D, Bajnok A, et al. Altered activation of peripheral CD8+ T cells in pediatric Crohn’s disease. Immunol Lett. 2017 May;185:48–51.
   PubMed Web of Science ®Google Scholar
• Valverde P, Kawai T, Taubman MA. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res. 2004 Jan;19(1):155–64. doi: 10.1359/jbmr.0301213
   PubMed Web of Science ®Google Scholar
• Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012 Jan;64(1):102–46.
   PubMed Web of Science ®Google Scholar
• Chimote AA, Hajdu P, Sfyris AM, et al. Kv1.3 channels mark functionally competent CD8+ tumor-infiltrating lymphocytes in head and neck cancer. Cancer Res. 2017 Jan 1;77(1):53–61. doi: 10.1158/0008-5472.CAN-16-2372
   PubMed Web of Science ®Google Scholar
• Moogk D, da Silva IP, Ma MW, et al. Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. J Transl Med. 2014 Dec 10;12(1):342. doi: 10.1186/s12967-014-0342-7
   PubMedGoogle Scholar
• Goggi JL, Khanapur S, Ramasamy B, et al. Imaging Kv1.3 expressing memory T cells as a marker of immunotherapy response. Cancers (Basel). 2022 Feb 26;14(5):1217. doi: 10.3390/cancers14051217
   PubMed Web of Science ®Google Scholar
• Newton HS, Gawali VS, Chimote AA, et al. PD1 blockade enhances K + channel activity, Ca 2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer. J Immunother Cancer. 2020 Oct;8(2):e000844.
   PubMed Web of Science ®Google Scholar
• Ehring GR, Kerschbaum HH, Eder C, et al. A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K+ channels, Ca2+ signaling, and gene expression in T lymphocytes. J Exp Med. 1998 Nov 2;188(9):1593–602. doi: 10.1084/jem.188.9.1593
   PubMed Web of Science ®Google Scholar
• Triantafilou K, Ward CJK, Czubala M, et al. Differential recognition of HIV-stimulated IL-1beta and IL-18 secretion through NLR and NAIP signalling in monocyte-derived macrophages. PLoS Pathog. 2021 Apr;17(4):e1009417.
   PubMed Web of Science ®Google Scholar
• Dellis O, Bouteau F, Guenounou M, et al. HIV-1 gp160 decreases the K+ voltage-gated current from Jurkat E6.1 T cells by up-phosphorylation. FEBS Lett. 1999 Jan 25;443(2):187–91. doi: 10.1016/S0014-5793(98)01691-3
   PubMed Web of Science ®Google Scholar
• Grgic I, Wulff H, Eichler I, et al. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc. 2009 Jul;41(6):2601–6.
   PubMed Web of Science ®Google Scholar
• Freidin MB, Bragina E, Saltykova IV, et al. Effect of additional disease (comorbidity) on association of allergic rhinitis with KCNE4 gene rs12621643 variant. Russ J Genet. 2013 Apr;49(4):541–544.
   Web of Science ®Google Scholar
• Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009 Sep;41(9):1001–5.
   PubMed Web of Science ®Google Scholar
• Selvakumar P, Fernandez-Marino AI, Khanra N, et al. Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators. Nat Commun. 2022 Jul 4;13(1):3854. doi: 10.1038/s41467-022-31285-5
   PubMed Web of Science ®Google Scholar